JNJ

238.9

+1.85%↑

UNH

271.02

-2.8%↓

TMO

552.32

-3.65%↓

ABT

109.1

+0.24%↑

ISRG

482.13

+1.33%↑

JNJ

238.9

+1.85%↑

UNH

271.02

-2.8%↓

TMO

552.32

-3.65%↓

ABT

109.1

+0.24%↑

ISRG

482.13

+1.33%↑

JNJ

238.9

+1.85%↑

UNH

271.02

-2.8%↓

TMO

552.32

-3.65%↓

ABT

109.1

+0.24%↑

ISRG

482.13

+1.33%↑

JNJ

238.9

+1.85%↑

UNH

271.02

-2.8%↓

TMO

552.32

-3.65%↓

ABT

109.1

+0.24%↑

ISRG

482.13

+1.33%↑

JNJ

238.9

+1.85%↑

UNH

271.02

-2.8%↓

TMO

552.32

-3.65%↓

ABT

109.1

+0.24%↑

ISRG

482.13

+1.33%↑

Home・Aktien・Pulmatrix Inc

Pulmatrix Inc

Open

2.5 -4.58

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.5

Max

2.62

Schlüsselkennzahlen
By Trading Economics
Einkommen	672K -877K
EPS	-0.24
Gewinnspanne	-60,266.667
Angestellte	2
EBITDA	671K -877K

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-8.4M 9.5M
Vorheriger Eröffnungskurs	7.08
Vorheriger Schlusskurs	2.5

Pulmatrix Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Feb. 2026, 00:00 UTC

Heiße Aktien

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4. Feb. 2026, 22:55 UTC

Ergebnisse

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4. Feb. 2026, 21:44 UTC

Ergebnisse

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4. Feb. 2026, 21:39 UTC

Ergebnisse

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

5. Feb. 2026, 00:00 UTC

Ergebnisse

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

5. Feb. 2026, 00:00 UTC

Ergebnisse

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

4. Feb. 2026, 23:46 UTC

Market Talk

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4. Feb. 2026, 23:45 UTC

Ergebnisse

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4. Feb. 2026, 23:32 UTC

Market Talk

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4. Feb. 2026, 22:59 UTC

Akquisitionen, Fusionen, Übernahmen

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4. Feb. 2026, 22:30 UTC

Ergebnisse

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4. Feb. 2026, 22:30 UTC

Ergebnisse

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4. Feb. 2026, 22:21 UTC

Ergebnisse

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4. Feb. 2026, 22:17 UTC

Market Talk

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4. Feb. 2026, 22:15 UTC

Market Talk

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4. Feb. 2026, 22:00 UTC

Market Talk

ESG Roundup: Market Talk

4. Feb. 2026, 21:53 UTC

Ergebnisse

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4. Feb. 2026, 21:51 UTC

Ergebnisse

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4. Feb. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4. Feb. 2026, 21:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

4. Feb. 2026, 21:50 UTC

Market Talk

Ergebnisse

Auto & Transport Roundup: Market Talk

4. Feb. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

4. Feb. 2026, 21:45 UTC

Ergebnisse

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4. Feb. 2026, 21:44 UTC

Ergebnisse

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4. Feb. 2026, 21:43 UTC

Ergebnisse

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4. Feb. 2026, 21:41 UTC

Ergebnisse

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4. Feb. 2026, 21:36 UTC

Market Talk

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4. Feb. 2026, 21:30 UTC

Ergebnisse

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4. Feb. 2026, 21:30 UTC

Ergebnisse

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4. Feb. 2026, 21:30 UTC

Ergebnisse

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Peer-Vergleich

Kursveränderung

Pulmatrix Inc Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pulmatrix Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.